NCT04457180View on ClinicalTrials.gov

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 16, 2020

Primary Completion Date

May 20, 2021

Study Completion Date

June 19, 2021

Conditions

Advanced Solid Tumor

Interventions

DRUG

Apatinib Mesylate

Apatinib will be administered daily from on D5 through D16

DRUG

Repaglinide

Repaglinide will be administered daily on D1 and D12

DRUG

Bupropion

Bupropion will be administered daily on D2 and D13

Trial Locations (1)

201203

The First Affiliated Hospital of University of Science and Technology of China, Hefei

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04457180 - A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects | Biotech Hunter | Biotech Hunter